α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas
E. Dodagatta-Marri, D. S. Meyer, M. Q. Reeves, R. Paniagua, M. D. To, M. Binnewies, M. L. Broz, H. Mori, D. Wu, M. Adoumie, R. Del Rosario, O. Li, T. Buchmann, B. Liang, J. Malato, F. Arce Vargus, D. Sheppard, B. C. Hann, A. Mirza, S. A. Quezada, M. D. Rosenblum, M. F. Krummel, A. Balmain, R. J. Akhurst
Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 62; DOI: 10.1186/s40425-018-0493-9
